Carlyle & SK Capital to Acquire Bluebird Bio
Shots:
- Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25
- As per the deal, Bluebird stockholders will get $3/share & contingent value right (CVR)/share allowing stockholders to receive additional $6.84/CVR in cash if Bluebird achieves $600M in net sales within 12mos. trailing period ending on Dec 31, 2027
- Bluebird has also amended loan terms with Hercules Capital to secure liquidity for sustaining operations until closing
Ref: Businesswire | Image: Bluebird Bio
Related News:- Carlyle to Acquire Baxter International’s Vantive Kidney Care Segment for $3.8B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
